Search From Over Half a Million Titles


Pharmaceuticals and Healthcare » Pharmaceuticals » Pharmaceuticals

Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast – 2025

  • ID:RM0034235
  • Published: September-2017
  • Pages:70
  • DelveInsight
1 of 3

DelveInsight’s “Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.

This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast. It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Renal cell carcinoma - Market InsShow More

1 of 3

1. Report Introduction
2. Renal cell carcinoma Market Overview at a Glance
2.1. Total Market Share Distribution of Renal cell carcinoma for 7 MM in 2016
2.2. Total Market Share Distribution of Renal cell carcinoma for 7 MM in 2025
3. Renal cell carcinoma
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment
4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Renal cell carcinoma in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Renal cell carcinoma in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Renal cell carcinoma in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Renal cell carcinoma in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Renal cell carcinoma in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Renal cell carcinoma in United Kingdom
5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices
6. Marketed Drugs for Renal cell carcinoma
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status
7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase
8. Overview of Total Renal cell carcinoma Market (2016 & 2025)
9. Renal cell carcinoma: Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)
10. Market Drivers
11. Market Restraints
12. Appendix
13. Report Methodology
14. Consulting Services
15. Disclaimer
16. About DelveInsight


List of Tables

Table 1: Diagnosed Cases Renal cell carcinoma in United States (2015-2025)
Table 2: Diagnosed Cases Renal cell carcinoma in Germany (2015-2025)
Table 3: Diagnosed Cases Renal cell carcinoma in France (2015-2025)
Table 4: Diagnosed Cases Renal cell carcinoma in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Renal cell carcinoma in Spain (2015-2025)
Table 6: Diagnosed Cases Renal cell carcinoma in Italy (2015-2025)
Table 7: Diagnosed Cases Renal cell carcinoma in Japan (2015-2025)
Table 8: List of Marketed Drugs for Renal cell carcinoma
Table 9: List of Pipeline Phase III Drugs for Renal cell carcinoma
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 17: Germany Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 18: France Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 20: Spain Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 21: Italy Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 22: Japan Market Size of Renal cell carcinoma in USD, Million (2015-2025)

List of Figures
Figure 1: Diagnosed Cases Renal cell carcinoma in United States (2015-2025)
Figure 2: Diagnosed Cases Renal cell carcinoma in Germany (2015-2025)
Figure 3: Diagnosed Cases Renal cell carcinoma in France (2015-2025)
Figure 4: Diagnosed Cases Renal cell carcinoma in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Renal cell carcinoma in Spain (2015-2025)
Figure 6: Diagnosed Cases Renal cell carcinoma in Italy (2015-2025)
Figure 7: Diagnosed Cases Renal cell carcinoma in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Renal cell carcinoma
Figure 9: List of Pipeline Phase III Drugs for Renal cell carcinoma
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 17: Germany Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 18: France Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 20: Spain Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 21: Italy Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 22: Japan Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Renal cell carcinoma Market (7MM)
Renal cell carcinoma Market forecasting
Renal cell carcinoma Sales forecasting
Renal cell carcinoma Market segments
Renal cell carcinoma Epidemiology
Renal cell carcinoma Pipeline products and technologies
Renal cell carcinoma Competitive landscape
Renal cell carcinoma SWOT analysis
Renal cell carcinoma Market Driver’s and barriers
Renal cell carcinoma Key Companies and Funding


List Of Tables

Table 1: Diagnosed Cases Renal cell carcinoma in United States (2015-2025)
Table 2: Diagnosed Cases Renal cell carcinoma in Germany (2015-2025)
Table 3: Diagnosed Cases Renal cell carcinoma in France (2015-2025)
Table 4: Diagnosed Cases Renal cell carcinoma in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Renal cell carcinoma in Spain (2015-2025)
Table 6: Diagnosed Cases Renal cell carcinoma in Italy (2015-2025)
Table 7: Diagnosed Cases Renal cell carcinoma in Japan (2015-2025)
Table 8: List of Marketed Drugs for Renal cell carcinoma
Table 9: List of Pipeline Phase III Drugs for Renal cell carcinoma
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 17: Germany Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 18: France Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 20: Spain Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 21: Italy Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Table 22: Japan Market Size of Renal cell carcinoma in USD, Million (2015-2025)


List of Figures

Figure 1: Diagnosed Cases Renal cell carcinoma in United States (2015-2025)
Figure 2: Diagnosed Cases Renal cell carcinoma in Germany (2015-2025)
Figure 3: Diagnosed Cases Renal cell carcinoma in France (2015-2025)
Figure 4: Diagnosed Cases Renal cell carcinoma in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Renal cell carcinoma in Spain (2015-2025)
Figure 6: Diagnosed Cases Renal cell carcinoma in Italy (2015-2025)
Figure 7: Diagnosed Cases Renal cell carcinoma in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Renal cell carcinoma
Figure 9: List of Pipeline Phase III Drugs for Renal cell carcinoma
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 17: Germany Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 18: France Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 20: Spain Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 21: Italy Market Size of Renal cell carcinoma in USD, Million (2015-2025)
Figure 22: Japan Market Size of Renal cell carcinoma in USD, Million (2015-2025)

1 of 3

Type Delivery Format Details
Hard Copy A printed copy of the report will be shipped to you.
CD-ROM The report will be shipped to you in CD ROM format.
SINGLE USER Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows one specific user access to the product.
SITE LICENSE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all users within a given geographical location of your organization access to the product.
ENTERPRISEWIDE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all employees within your organization in different geographic locations access to the product.
1 - 5 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to five users have access to the product.
1 – 10 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to ten users have access to the product.
1 – 15 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to fifteen users have access to the product.
1 - 5 USERS Online Access (For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to five users have access to the product.
1 - 10 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to ten users have access to the product.
1 - 15 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to fifteen users have access to the product.
1 - 5 USERS Electronic (Excel) The Excel spreadsheet will be emailed to you. The license allows up to five users have access to the product.

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-10 user licence, allowing up to ten users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.